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ROLE OF HELICOBACTER PYLORI INFECTION IN DEVELOPMENT OF GASTROINTESTINAL
MALIGNANCY
Zilola Khashimova, MD, MBA, SP, Assistant Professor, MSPAS Program, Dominican
University of California, California, United States of America
Introduction. Helicobacter Pylori (HP) infection has been associated with chronic inflammation of the stomach
and may also be associated with the development of gastrointestinal malignancy.
Purpose of Study: This study will examine the literature related to HP infection associated with the cancers
of the stomach.
Materials and Methods: A literature review was conducted on the reported research of HP infection associated
with gastric cancer cases.
Results and Discussions: Helicobacter pylori is a gastric pathogen that colonizes approximately 50% of
the world’s population. Infection with H. pylori causes chronic inflammation and significantly increases the risk of
developing duodenal and gastric ulcer disease and gastric cancer. Infection with H. pylori is the strongest known
risk factor for gastric cancer, which is the second leading cause of cancer-related deaths worldwide. Once H. pylori
colonizes the gastric environment, it persists for the lifetime of the host, suggesting that the host immune response
is ineffective in clearing this bacterium. In this review, we discuss the host immune response and examine other
host factors that increase the pathogenic potential of this bacterium, including host polymorphisms, alterations to
the apical-junctional complex, and the effects of environmental factors.In addition to host effects and responses,
H. pylori strains are genetically diverse. [69]
Conclusions: The exact mechanism to explain the role of H. pylori in carcinogenesis is incompletely
understood. Multiple studies have demonstrated an association between H. pylori infection and mucosa-associated
lymphoid tissue lymphoma (MALToma). The most dramatic evidence supporting a pathogenetic role for H. pylori
in MALToma is remission of the tumor following eradication of H. pylori with antibiotic therapy. [42]
Key Words: helicobacter Pylori, Idiopathic thrombocytopenic purpura, peptic ulcer, chronic gastritis, gastric
B cell lymphoma, hemostasis, autoimmune, hematological pathologies, gastric atrophy, platelets, gastric cancer.
ОШҚОЗОН-ИЧАК
САРАТОНИНИ
РИВОЖЛАНИШИДА
HELICOBACTER
PYLORI
ИНФЕКТЦИЯСИНИНГ АҲАМИЯТИ
Кириш: Helicobacter Pylori (HP) инфекцияси ошқозоннинг сурункали яллиғланиши ҳамда ошқозон-ичак
трактинингсаратон касалликлари ривожланиши билан боғлиқ бўлиши мумкин.
Тадқиқот мақсади: HP инфекциясини ошқозон-ичак трактида саратон касаллигини ривожланишига
таъсири билан боғлиқ илмий тадқиқотлар ва адабиётларни кўриб чиқиш.
Материаллар ва усуллар: HP инфекциясини ошқозон-ичак трактида саратон касаллигини
ривожланишига таъсири қилувчи механизмларни ўрганиш бўйича илмий адабиётларни ўрганилди.
Натижалар ва уларнинг муҳокамаси: HP - бу ошқозон патогени бўлиб, дунё аҳолисининг тахминан
50 фоизига ўз таъсирини кўрсатади. HP инфекцияси сурункали яллиғланишни келтириб чиқаради ва
ўн икки бармоқли ичак ва ошқозон яраси ҳамда ошқозон саратони ривожланиш хавфини сезиларли
даражада оширади. HP инфекцияси ошқозон саратони учун энг асосий хавф омили хисобланиб,
саратон касаллигидан ўлимга сабаб бўлишда иккинчи ўринда туради. HP ошқозонга муҳитига тушиши
билан беморнинг бутун ҳаёти давомида сақланиб қолади, бу эса бактерияни нейтраллашда беморнинг
иммун таъсири самарасиз эканлигидан далолат беради. Ушбу шарҳда биз беморнинг иммун таъсирини
муҳокама қиламиз ва бактериянинг патоген потенциалини оширадиган бошқа омилларни, шу жумладан
бемор полиморфизмларини, апикал-бирикма комплексидаги ўзгаришларни ва атроф-муҳит омилларининг
таъсирини ўрганамиз. Шуни ҳам қўшимча қилиш керакки HP штаммларининг таъсири ва реакциялари
хилма-хилдир [69].
Хулоса. HPнинг кансерогенезни хосил бўлишдаги аҳамияти тўлиқ ўрганилмаган. Кўплаб тадқиқотлар
HP инфекциясини шиллиқ қават (МAЛТ лимфома)билан боғлиқ бўлган лимфа тўқималари лимфомаси
ўртасидаги алоқани мавжудлигини кўрсатмоқда. Энг ишончли далилларга биноан HP МAЛТомада
патогенетик аҳамияти кўрсатилиб, антибиотик терапияси билан HP эридикация қилинганда ўсманинг
ремиссияси кузатилади [42].
Калит сўзлар: helicobacter pylori, идиопатик тромбоцитопеник пурпура, ошқозон яраси, сурункали
гастрит, ошқозоннинг Б-ҳужайрали лимфомаси, гемостаз, аутоиммун касалликлар, гематологик патология,
ошқозон атрофияси, тромбоцитлар, ошқозон саратони.
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РОЛЬ ИНФЕКЦИИ HELICOBACTER PYLORIВ РАЗВИТИИ
ЖЕЛУДОЧНО-КИШЕЧНЫХ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
Введение: Инфекция Helicobacter Pylori (HP) связана с хроническим воспалением желудка и может
также быть связана с развитием желудочно-кишечных злокачественных новообразований.
Цель исследования: в этом исследовании проведен обзор научных исследований и литературы,
связанных с инфекцией HP, и её влияние на развитие желудочно-кишечных злокачественных
новообразований.
Материалы и методы исследования. Был проведен обзор научной литературы по исследованию
инфекции HP и механизм влияния НР-инфекции на развитие желудочно-кишечных злокачественных
новообразований.
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Introduction. Helicobacter pylori (H. pylori) is
present in over 50% of all stomachs in the world
population, making it the most frequent infection
in humans[1]. It displays a marked disparity in occurrence between developed countries, where its
prevalence oscillates between 30% and 50%, and
developing countries, where its prevalence ranges between 80% and 90%[2].
After 1983, when it was discovered that the
stomach could be colonized by bacteria[3], increasing evidence has shown that H. pylori is a
pathogen closely related to a variety of gastric
conditions. These range from benign stomach
diseases such as chronic gastritis, duodenal peptic ulcers and gastric peptic ulcers[3] to malignant
diseases such as gastric cancer[4] and gastric
mucosa-associated lymphoid tissue (MALT) lymphoma[5].
Helicobacter pylori (H. pylori) is the most common infection in humans, with a marked disparity between developed and developing countries.
Although H. pylori infections are asymptomatic in
most infected individuals, they are intimately related to malignant gastric conditions such as gastric
cancer and gastric mucosa-associated lymphoid
tissue (MALT) lymphoma and to benign diseases
such as gastritis and duodenal and gastric peptic
ulcers. Since it was learned that bacteria could
colonize the gastric mucosa, there have been
reports in the medical literature of over 50 extragastric manifestations involving a variety medical areas of specialization. These areas include
cardiology, dermatology, endocrinology, gynecology and obstetrics, hematology, pneumology,
odontology, ophthalmology, otorhinolaryngology
and pediatrics, and they encompass conditions
with a range of clear evidence between the H.
pylori infection and development of the disease.
Helicobacter pylori (H. pylori) infections are intimately related to malignant gastric conditions and

benign diseases in the stomach [6].
Purpose of Study. Helicobacter pylori is the
dominant species of the human gastric microbiome, and colonization causes a persistent inflammatory response. H. pylori-induced gastritis
is the strongest singular risk factor for cancers
of the stomach; however, only a small proportion of infected individuals develop malignancy.
Carcinogenic risk is modified by strain-specific bacterial components, host responses and/or
specific host–microbe interactions. Delineation of
bacterial and host mediators that augment gastric cancer risk has profound ramifications for
both physicians and biomedical researchers as
such findings will not only focus on the prevention
approaches that target H. pylori-infected human
populations at increased risk for stomach cancer
but will also provide mechanistic insights into inflammatory carcinomas that develop beyond the
gastric niche. [69]
Materials and Methods. A literature review
was conducted of reported research of the association of HP infection and gastric cancer cases.
ResultsandDiscussion
KeyPoints
Infection with Helicobacter pylori is the strongest known risk factor for gastric adenocarcinoma, but only a minority of colonized individuals
develop cancer of the stomach.
H. pylori strains exhibit extensive genetic diversity and strain-specific proteins augment the
risk for malignancy.
β-catenin signaling has an important role in
conjunction with other oncogenic pathways in the
regulation of host responses to H. pylori that have
carcinogenic potential.
Transactivation of epidermal growth factor receptor may help us understand the epithelial signaling pathways that mediate H. pylori-induced
carcinogenesis.
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Результаты и их обсуждения. Helicobacterpylori является желудочным патогеном, который
колонизирует приблизительно 50% населения мира. Инфекция H. pylori вызывает хроническое воспаление
и значительно увеличивает риск развития язвенной болезни двенадцатиперстной кишки и желудка, а
также рака желудка. Инфекция H. pylori является наиболее известным фактором риска развития рака
желудка, который является второй по значимости причиной смертности от рака во всем мире. Как только
H. pylori колонизирует желудочную среду, она сохраняется в организме в течение всей жизни хозяина, что
свидетельствует о том, что иммунный ответ хозяина неэффективен при обезвреживании этой бактерии.
В этом обзоре мы обсуждаем иммунный ответ хозяина и исследуем другие факторы хозяина, которые
увеличивают патогенный потенциал этой бактерии, включая полиморфизмы хозяина, изменения в
апикально-соединительном комплексе и влияние факторов окружающей среды. В дополнение к эффектам
и реакциям хозяина, штаммы H. pylori генетически разнообразны [69].
Выводы. Точный механизм объяснения роли H. pylori в канцерогенезе до конца не изучен.
Многочисленные исследования продемонстрировали связь между инфекцией H. pylori и лимфомой
лимфатической ткани, ассоциированной со слизистой оболочкой (MALTлимфома). Наиболее убедительным
доказательством, подтверждающим патогенетическую роль H. pylori в MALToma, является ремиссия
опухоли после эрадикации H. pylori с помощью антибиотикотерапии. [42]
Ключевые слова:HelicobacterPylori, идиопатическая тромбоцитопеническая пурпура, язвенная болезнь
желудка, хронический гастрит, B-клеточная лимфома желудка, гемостаз, аутоиммунные заболевания,
гематологические патологии, атрофия желудка, тромбоциты, рак желудка.
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Chronic inflammation can induce aberrant
β-catenin activation in the context of H. pylori
infection.
A mechanistic understanding of H. pylori activation of oncogenic signaling may lead to key
insights into malignancies that arise from inflammatory foci in other organ systems [7].
Gastric adenocarcinoma is the second leading cause of cancer-related death in the world
[1]. Epidemiological and interventional studies
in humans, as well as experiments in rodents,
have associated Helicobacter pylori — a member
of a large family of related bacteria that colonize
the mammalian stomach — with peptic ulcers,
non-Hodgkin’s lymphoma of the stomach, gastric
atrophy and distal gastric adenocarcinoma [1018]. However, only a small percentage (probably
less than 3%) of individuals that carry H. pylori
ever develop neoplasias related to its presence,
indicating that other factors are involved. Such
observations, along with recent evidence that certain H. pylori strains might reduce the risk of GASTROESOPHAGEAL REFLUX DISEASE (GERD)
and its complications (for example, oesophageal
adenocarcinoma) [19, 20], underscore the importance of understanding the biological interactions
of these organisms with their host [9].
H. pylori and gastric cancer
Two histologically distinct variants of gastric
adenocarcinoma have been described, each having different epidemiological and pathophysiological features. Intestinal-type gastric adenocarcinoma usually occurs at a late age, predominates in
men and progresses through a relatively well-defined series of histological steps [8]. Diffuse-type
gastric adenocarcinoma more commonly affects
younger people, affects men and women equally
and consists of individually infiltrating neoplastic
cells that do not form glandular structures and are
not associated with intestinal metaplasia[21].
The chain of events that occurs during development of intestinal-type gastric cancer involves
a transition from normal mucosa to chronic superficial GASTRITIS, which then leads to ATROPHIC
GASTRITIS and INTESTINAL METAPLASIA, and
finally to DYSPLASIA and ADENOCARCINOMA.
The ability of H. pylori to induce superficial gastritis [22], however, indicates that this organism —
or the host inflammatory response to it — could
be important in the initiation and promotion of
gastric neoplasia. [9].
Histologically, two distinct variants of gastric carcinoma have been identified: diffuse-type
gastric cancer, which consists of individually infiltrating neoplastic cells that do not form glandular
structures; and intestinal-type adenocarcinoma,
which progresses through a series of well-defined
histological steps and was first described in 1975

[22, 23] (Fig. 1). Intestinal-type adenocarcinoma
is initiated by the transition from normal mucosa
to chronic superficial gastritis; this is followed by
atrophic gastritis and intestinal metaplasia, finally leading to dysplasia and adenocarcinoma [22,
24, 25]. This form of gastric cancer affects men
twice as commonly as women and occurs in men
with a mean age of 50.4 years and in women with
a mean age of 47.7 years.Corpus-predominant
gastritis predisposes individuals toward gastric
cancer, which is thought to be due in part to decreased acid secretion. In contrast, infection primarily of the gastric antrum results in increased
acid production and predisposes individuals to
duodenal ulcer disease, which is associated with
a decreased risk of gastric cancer [22].
Multifactorial pathway leading to gastric carcinoma. Many host, bacterial, and environmental factors act in combination to contribute to the
precancerous cascade leading to development of
gastric cancer.
H. pylori can cause chronic active gastritis and
atrophic gastritis, early steps in the carcinogenesis
sequence [26, 27]. In animal models, H. pylori infection has induced gastric adenocarcinoma [28].
Furthermore, a number of studies in humans have
demonstrated a clear association between H. pylori infection and gastric adenocarcinoma [29-31].
The link has been demonstrated in both the intestinal and diffuse subtypes of gastric cancer [29,32].
The relationship between H. pylori infection
and gastric carcinogenesis in humans can be illustrated by the following observations:
●H. pylori has been identified histologically in
the uninvolved mucosa from stomachs harboring
cancers or precancerous changes e.g. atrophic
gastritis with or without accompanying intestinal
metaplasia [33,34].
●Epidemiologic studies demonstrate a strong
correlation between H. pylori seropositivity and
gastric cancer. As an example, the EUROGAST
study of 17 populations from 13 different countries
(11 European countries, the United States, and
Japan) found a six fold increased risk of gastric
cancer in H. pylori-infected populations compared
with uninfected populations [35]. Similar findings
have been noted in nested-case control studies
in which the stored serum of patients with known
gastric adenocarcinoma and that of matched controls were tested for H. pylori IgG antibody. H.
pylori infection was associated with odds ratios
ranging from 2.8 to 49 and attributable risks of 46
to 63 percent [31,36-39]. In a nested case control
study of Japanese Americans living in Hawaii, for
example, H. pylori seropositivity was present in
94 percent of patients with gastric cancer compared with 76 percent of matched controls; the
odds ratio was 6.0 [37].
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FIG. 1.
●Two meta-analyses of cohort and case
control studies examining the relationship
between H. pylori seropositivity and gastric cancer
found that H. pylori infection was associated with
a twofold increased risk for developing gastric
adenocarcinoma [29,30]. The relative risk for
gastric cancer was greatest for younger patients
(9.29 at age less than 29) in whom the absolute
risk is still quite low [29].
One of the largest prospective studies
addressing H. pylori and cancer risk included 1,526
Japanese patients of whom 1,246 had H. pylori
infection [40]. Patients underwent endoscopy
with biopsy at enrollment and then between one
and three years after enrollment. During a mean
follow-up of 7.8 years, 36 patients developed
gastric cancer (2.9 percent), all of whom were H.
pylori infected. No uninfected patient developed
cancer.
The International Agency for Research on
Cancer estimates that 36 and 47 percent of all
gastric cancers in developed and developing
countries, respectively, are solely attributable to H.
pylori infection. This accounts for almost 350,000
gastric cancers annually worldwide. One report
indicated that of the 12.7 million new cancers

occurring in 2008, the population attributable
fraction due to infections was over 16 percent for
H. pylori [41,42].
Despite the clear association between H. pylori
and gastric adenocarcinomas, only a minority of
infected individuals will develop gastric cancer. It
is thought that modulation of the effects of infection
by external, mostly environmental factors (and
possibly strain differences in H. pylori, see below)
influence whether infection results in a neoplastic
or non-neoplastic process.[42]
Role of H. pylori in carcinogenesis —
Several hypotheses have been proposed to
explain the role of H. pylori in carcinogenesis,
although the exact mechanism is incompletely
understood [42,43]. At present, it is believed
that bacterial properties, host response, and
environmental factors all play a role.
H. pylori strain differences — The strain of
H. pylori also may be a determinant of its potential
to cause cancer or ulcer disease.
Host immune responses — Host genetics
that regulate the immune response and mucosal
events that result from infection play important
roles in gastric cancer development in chronically
infected individuals [42].

73

Обзорные статьи

Ежеквартальный научно-практический журнал

74

Cytokine polymorphisms — Certain
polymorphisms in IL-1 beta and other cytokines
may confer an increased susceptibility to noncardia gastric adenocarcinoma caused by
H. pylori by inducing a hypochlorhydric and
atrophic response to H. pylori infection [42,4449]. An illustrative study compared IL-1 beta
polymorphisms in 393 patients with gastric
cancer with 430 controls [42,44]. Two specific
polymorphisms (IL-1B-31T and IL-1RN*2) were
associated with low acid secretion and gastric
atrophy. The authors concluded that 38 percent of
H. pylori-related gastric cancer could be attributed
to the presence of these alleles. IL-1 beta, a potent
inhibitor of gastric acid secretion, is upregulated
by the presence of H. pylori [42].
A similar report compared polymorphisms
in genes for several cytokines in patients with a
variety of gastric and esophageal malignancies
with a control population [42,45]. Proinflammatory
genotypes of tumor necrosis factor alpha and IL10 were associated with more than a doubling of
the risk of non-cardia gastric cancer. Carriage of
multiple proinflammatory polymorphisms of IL-1
beta, IL-1 receptor antagonist, tumor necrosis
factor A, and IL-10 conferred even greater risk
(OR 2.8 for one, 5.4 for two, and 27.3 for more
than three). By contrast, these polymorphisms
were not associated with an increased risk of
esophageal or gastric cardia cancers.[42]
These data suggest that gene polymorphisms
influence
cytokine
expression,
gastric
inflammation, and risk for development of
precancerous lesions in those infected with H.
pylori. Infection with certain virulent bacterial
strain types augments inflammation and cancer
risk, supporting a complex interaction between
host and bacterial in the development of GI
pathology [50].
Neutrophil activation — One hypothesis has
been demonstrated in vitro. CD11a/CD18- and
CD11b/CD18-neutrophils, induced by H. pylori
infection, interact with intercellular adhesion
molecule-1 (ICAM-1), resulting in the migration of
neutrophils to the site of infection and adhesion to
the surface epithelium. The recruited neutrophils
then produce inducible nitric oxide synthase
and release nitric oxide and reactive oxygen
metabolites, such as superoxide and hydroxyl
ions, which in turn damage DNA. This is followed
by mutation and malignant transformation. H.
pylori induces oxidative stress in epithelial cells
[51].
Epithelial responses — H. pylori and the
immune response induce altered rates of gastric
epithelial cell growth and death, which involve
various signaling pathways leading to apoptosis,

proliferation, differentiation, and autophagy [42].
Apoptotic pathways — Two important
processes in carcinogenesis are apoptosis
(programmed cell death) and hyperproliferation
[52]. Following severe DNA damage, apoptosis
occurs as a protective mechanism to prevent
replication of mutated DNA. Atrophic gastritis
with destruction and loss of the glands could
be the result of apoptosis. This hypothesis is
supported by the finding of an increased rate of
antral apoptosis in H. pylori-infected subjects
[42,53,54], which returns to normal following
eradication therapy [53]. The mechanism by which
H. pylori induces apoptosis is unclear. One study
suggested that the organism causes apoptosis by
both direct and indirect mechanisms [55]. In the
latter circumstance, H. pylori appears to sensitize
epithelial cells for apoptosis which is induced
by proinflammatory stimuli (e.g. tumor necrosis
factor alpha). H. pylori enhances expression of the
Fas receptor on gastric epithelial cells and may
mediate apoptosis through signaling mechanisms
related to the Fas death receptor [56]. Proliferating
cells may be resistant to apoptosis. This would
upset the balance between cell growth and death,
leading to hyperproliferation and the promotion of
neoplasia [57]. There is evidence of an increased
amount of the anti-apoptosis protein, Bcl-2, in the
setting of gastric dysplasia [58]. Other reports have
found that apoptosis may be due to plasminogen
activator inhibitor (PAI)-2, the expression of which
is increased by H. pylori. PAI-2 is increased in
gastric cancer [59]. An uncoupling of epithelial
proliferation and apoptosis may be a straindependent phenomenon. Hyperproliferation has
been seen in CagA-infected patients in whom
apoptosis is not increased [60].
Cell signaling events — One report indicated
that c-Src and c-Abl kinases sequentially
phosphorylate CagA [61]. The two phosphorylation
events need not occur on the same CagA
molecule but are both required for the biological
effects of CagA. Another study demonstrated that
vacuolating cytotoxin and variants in Atg16L1
disrupt autophagy and promote H. pylori infection
in humans. As autophagy protects against
infection with H. pylori, this could contribute to
inflammation and eventual carcinogenesis [62].
A potentially important observation is that the
source of gastric cancer may not be from gastric
epithelial cells themselves but rather from bone
marrow-derived cells that differentiate into gastric
epithelial cells in the presence of H. pylori [63].
If this observation is confirmed, it would have
significant implications for the treatment of
H. pylori-associated gastric cancer as well as
other epithelial cancers associated with chronic
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gastric cancer as compared with those who did
not receive eradication therapy (pooled incidence
rate ratio 0.53; 95% CI 0.44-0.64). As compared
with individuals in the lowest tertile of baseline
cancer incidence, those in the intermediate and
highest tertile of cancer incidence had a greater
reduction in gastric cancer incidence rate with
H. pylori eradication (incidence rate ratio 44
and 38 percent, respectively). The magnitude of
benefit was not significantly different between
asymptomatic individuals and those who had
undergone endoscopic resection of gastric cancer
[42].
Even if treatment does reduce the gastric
cancer risk, difficulties with screening for H.
pylori and treatment arise. The cost of screening
and treating would be large given the worldwide
prevalence of H. pylori infection. Nevertheless,
one study that economically modeled the cost
of screening per year of life saved estimated
that, in selected populations such as Japanese
American, serologic screening for H. pylori
beginning at age 50 was more beneficial than
breast cancer screening [65]. Another costeffectiveness analysis concluded that screening
and treatment could be cost-effective if the cancer
risk following eradication could be restored to that
of a population that had never been infected with
H. pylori [67].
A number of major medical organizations have
issued guidelines related to H. pylori screening
and eradication in high-risk populations. As
examples, Asian-Pacific guidelines and European
guidelines support population-based screening in
high-risk settings [67,68].
Approximately 36 and 47 percent of all gastric
cancers in developed and developing countries,
respectively, are solely attributable to H. pylori
infection. This accounts for almost 350,000 gastric
cancers annually worldwide.
Conclusion. Several hypotheses have
been proposed to explain the role of H. pylori in
carcinogenesis, although the exact mechanism
is incompletely understood. (See ‘Role of H.
pylori in carcinogenesis’ above.) Multiple studies
have demonstrated an association between H.
pylori infection and mucosa-associated lymphoid
tissue lymphoma (MALToma). The most dramatic
evidence supporting a pathogenetic role for H.
pylori in MALToma is remission of the tumor
following eradication of H. pylori with antibiotic
therapy [42].
Conflict of interest statement. Competing
interests: the authors of this paper have no conflict
of interest to disclose.

Обзорные статьи

inflammation [42].
Colon cancer—An association between
H. pylori infection and colorectal polyps and
colorectal cancer has been described but remains
controversial [70-81].
The biologic basis for such an association
is uncertain. One possibility is elevated serum
gastrin levels in patients with H. pylori infection
[71]. Gastrin receptors have been identified on a
variety of colon cancer cell lines, and endogenous
serum gastrin levels have been correlated with
the risk of colonic neoplasms. However, studies
have not found an association of serum gastrin
levels with an increased risk for colonic neoplasia
[77,80].
Pancreatic cancer—An association between
H. pylori infection and pancreatic cancer has been
reported [82-86]. In a meta-analysis that included
1083 patents with pancreatic cancer and 1950
controls, infection with H. pylori was associated
with an increased risk of pancreatic cancer (OR
1.47, 95% CI 1.2-1.8) [87]. On subgroup analysis,
CagA positive H. pylori strains were not associated
with an increased risk of pancreatic cancer.
Another report found an association between
colonization with non-CagA H. pylori strains and
pancreatic cancer in patients with non-O blood
types; no association was found in patients with
non-O blood types infected with CagA positive H.
pylori [84].
A possible mechanism proposed for the
association of pancreatic cancer and H. pylori is
the link between pancreatic cancer and chronic
hyperacidity [88]. Additional studies are needed
to confirm the association of pancreatic cancer
and H. pylori infection and also to better support
the putative role of hyperacidity.
Hepatobiliary cancer—Several studies report
an association between biliary tract carcinoma
and infection with H. pylori [89-93]. Although a
cause and effect relationship has not been proven,
some have suggested that H. pylori may be
involved in the pathogenesis of biliary neoplasms
through enhanced biliary cell inflammation and
proliferation [92, 94].
Does treatment reduce risk of gastric
cancer?
Eradication of H. pylori appears to reduce the
risk of gastric cancer. The magnitude of reduction
varies by the baseline incidence of gastric cancer,
but is seen even in populations with low gastric
cancer incidence. A meta-analysis of 27 studies
included 48,606 H. pylori infected individuals with
715 incident gastric cancers [64]. Individuals with
eradication of H. pylori had a lower incidence of
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